Literature DB >> 4405530

Changes in plasma -glutamyl transpeptidase activity associated with alterations in drug metabolism in man.

J B Whitfield, D W Moss, G Neale, M Orme, A Breckenridge.   

Abstract

A significant rise in plasma gamma-glutamyl transpeptidase activity (GGT) was observed on 13 out of 14 occasions on which patients on long-term treatment with the oral anticoagulant warfarin were given amylobarbitone, quinalbarbitone, or phenazone (antipyrine) for 30 days. In 13 of these 14 studies there was evidence that drug administration had stimulated the rate of warfarin metabolism. One patient showed no increase in plasma GGT activity, yet a significantly increased rate of warfarin metabolism, and another patient showed an increase in plasma GGT activity without a change in warfarin metabolism. When alterations in both plasma GGT activity and plasma warfarin concentration occurred together in response to drug administration the changes followed a similar time course, occurring after about one week of drug administration with maximal changes at about 10 or 15 days. Administration of chlordiazepoxide, diazepam, nitrazepam, and methaqualone did not stimulate the rate of warfarin metabolism in four patients studied, but plasma GGT activity increased significantly in two of these four instances. The implications of these observations in the interpretation of plasma GGT activities are discussed.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4405530      PMCID: PMC1588204          DOI: 10.1136/bmj.1.5849.316

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  10 in total

1.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

2.  Plasma gamma-glutamyl transpeptidase elevation in patients receiving enzyme-inducing drugs.

Authors:  S B Rosalki; D Tarlow; D Rau
Journal:  Lancet       Date:  1971-08-14       Impact factor: 79.321

3.  Interactions of benzodiazepines with warfarin.

Authors:  M Orme; A Breckenridge; R V Brooks
Journal:  Br Med J       Date:  1972-09-09

4.  Serum -glutamyl transpeptidase activity in alcoholism.

Authors:  S B Rosalki; D Rau
Journal:  Clin Chim Acta       Date:  1972-06       Impact factor: 3.786

5.  Clinical implications of enzyme induction.

Authors:  A Breckenridge; M Orme
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

6.  The assay of warfarin in plasma or stool.

Authors:  R J Lewis; L P Ilnicki; M Carlstrom
Journal:  Biochem Med       Date:  1970-12

7.  A kinetic photometric method for serum gamma-glutamyl transpeptidase.

Authors:  G Szasz
Journal:  Clin Chem       Date:  1969-02       Impact factor: 8.327

8.  Gamma-glutamyl transpeptidase: a clinical and experimental study.

Authors:  G Idéo; A Morganti; N Dioguardi
Journal:  Digestion       Date:  1972       Impact factor: 3.216

9.  Serum -glytamyl transpeptidase activity in liver disease.

Authors:  J B Whitfield; R E Pounder; G Neale; D W Moss
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

10.  Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine).

Authors:  A Breckenridge; M L Orme; S Thorgeirsson; D S Davies; R V Brooks
Journal:  Clin Sci       Date:  1971-04       Impact factor: 6.124

  10 in total
  33 in total

Review 1.  The scientific foundations of clinical enzymology.

Authors:  D W Moss
Journal:  Naturwissenschaften       Date:  1977-05

2.  The clinical consequences of chronic hepatic enzyme induction by anticonvulsant drugs.

Authors:  A Richens
Journal:  Br J Clin Pharmacol       Date:  1974-06       Impact factor: 4.335

3.  Phenprocoumon requirement, whole blood coagulation time, bleeding time and plasma gamma-GT in patients receiving mianserin.

Authors:  H Kopera; H Schenk; S Stulemeijer
Journal:  Eur J Clin Pharmacol       Date:  1978-07-30       Impact factor: 2.953

4.  Anticonvulsant therapy and serum gamma-glutamyl-transferase.

Authors:  R Heipertz; K Eickhoff; W Poser
Journal:  Klin Wochenschr       Date:  1978-09-15

5.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

6.  D-glucaric acid excretion in critical care patients--comparison with 6 beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapy.

Authors:  G Heinemeyer; I Roots; P Lestau; H R Klaiber; R Dennhardt
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

7.  Changes in the concentration of serum alpha 1-acid glycoprotein in epileptic patients.

Authors:  K Morita; A Yamaji
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years.

Authors:  E Walter; C Staiger; J de Vries; E Weber; W Bitzer; M Degott; K Jüngling
Journal:  Klin Wochenschr       Date:  1982-11-15

9.  Induction of drug metabolizing enzymes by sulfinpyrazone.

Authors:  E Walter; C Staiger; J de Vries; R Zimmermann; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 10.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.